Kaplan-Meier analysis of the TCGA prostate adenocarcinoma (TCGA-PRAD) dataset indicated that patients with combined high expression of HeyL and CYP19A1 had lower disease-free survival rates than those with combined low expression of HeyL and CYP19A1. Moreover, the expression of both HeyL and aromatase was significantly increased in CRPC. The gene discussed is CYP19A1; the disease is prostate adenocarcinoma.